Market/Novel Tech Articles
GenSight, a French biotechnology company, has announced the receipt of FDA orphan designation for retinitis pigmentosa gene therapy treatment in the US.
GenSight Biologics S.A. (Euronext: SIGHT) has announced the receipt of FDA Orphan Drug Designation in the US for its experimental retinitis pigmentosa (RP) treatment, “GS030”. The announcement follows a similar orhan designation grant in the EU, announced in Q4 of 2016. According to the company, GS030, is an optogenetic therapy delivered using adeno-associated viral (AAV) […]Read full story
Gap between real world treatment outcomes and clinical trial results of ocriplasmin highlighted in UK/Ireland study of VMA treatment
A survey among retinal specialists in the UK and Ireland has indicated that the real world outcome for patients with vitreomacular traction (VMT) and full thickness macular hole (FTMH), when treated with ocriplasmin, is significantly different to the results presented in clinical trials. A retrospective survey among members of the British and Eire Association of […]Read full story
GenSight Biologics Inc. reports sustained visual acuity 78 weeks after gene therapy treatment for Leber’s Hereditary Optic Neuropathy (LHON)
GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, have announced that their GS010 treatment for LHON provides sustained visual acuity 78 weeks after a dose escalating study in each cohort of 3 patients. The GS010 treatment comprises a wild-type functional copy of the mitochondrial ND4 gene, housed within an AAV2 vector and delivered via a single […]Read full story